Doxorubicin Market Size & Share, by Drug Formulation (Lyophilized Powder, Injection); Application (Bladder Cancer, Kaposi Sarcoma, Leukemia, Lymphoma, Breast Cancer, Ovarian Cancer, Multiple Myeloma, Kidney Cancer); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4876
  • Published Date: May 01, 2023
  • Report Format: PDF, PPT

Companies Dominating the Doxorubicin Landscape

top-features-companies
    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Johnson and Johnson
    • Zydus Group
    • Cipla Limited
    • Sun Pharmaceutical Industries Ltd
    • Padagis
    • Reddy Laboratories Ltd.,
    • Cadila Healthcare Limited
    • Novartis International AG
    • MicroBiopharm Japan Co. Ltd.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Ayana Pharma Ltd, in partnership with Padagis, received approval from the US FDA to launch a generic version of the drug Doxil (Doxorubicin Liposome Injection), which has been rated AB by the FDA.
  • Under a definitive merger agreement between Pfizer Inc. and Seagen Inc., Pfizer Inc. plans to acquire Seagen for USD 229 per Seagen share, for a total enterprise value of USD 43 billion. Seagen develops, commercializes, and discovers transformative cancer medicines.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4876
  • Published Date: May 01, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing prevalence of cancer and rising demand for targeted therapies are the major factors driving the market growth.

The market size of doxorubicin is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023-2035.

Strict regulations imposed by various governments and the lack of reimbursement are estimated to be the growth-hindering factors for market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Pfizer Inc., Johnson and Johnson, Zydus Group, Cipla Limited, Sun Pharmaceutical Industries Ltd, Padagis, Reddy Laboratories Ltd., Cadila Healthcare Limited, Novartis International AG, MicroBiopharm Japan Co. Ltd., And others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug formulation, application, distribution channel, and by region.

The doxorubicin injection segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying